1. PTEN-deficient prostate cancer cells exhibit constitutive macropinocytosis.
PTEN-deficient prostate cancer cells exhibit constitutive macropinocytosis. A, Dextran uptake in prostate cancer in 1% AA/gluc ± EIPA (50–75 μmol/L). B, Dextran uptake in RWPE-1 cells in complete medium (CM) or 1% AA/gluc ± A (50 μmol/L). C, Dextran uptake in mPCE cells ± PTEN reconstitution or a 1-hour pretreatment with the pan-PI3Ki ZSTK474 (200 nmol/L) or Compound C (10 μmol/L). D, Dextran uptake in GFP-positive DU145 cells 48 hours after transfection with plasmids expressing GFP or GFP and RAC1T17N, DN-AMPK, or WT PTEN. E and F, Dextran uptake in prostate cancer cell lines in CM ± EIPA (50–75 μmol/L), compared with results in 1% AA/gluc in F. G, Dextran index in prostate cancer cells incubated with dextran for 5 minutes in CM ± A (50 μmol/L). All panels except A and part of B were conducted in complete medium. Scale bars, 20 μm. Dextran index in white; means ± SEM shown with statistics relative to control, CM, or vector; ≥25 cells were examined. Using a paired two-tailed t test, *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; n.s., not significant. See also Supplementary Fig. S6.
Seong M. Kim et al. Cancer Discov 2018;8:
©2018 by American Association for Cancer Research